GDC 0214

Drug Profile

GDC 0214

Latest Information Update: 04 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genentech
  • Class Antiasthmatics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Asthma

Most Recent Events

  • 30 Aug 2017 Genentech plans a phase I trial for Asthma (In volunteers) in New Zealand in December 2017 (ACTRN12617001227381p)
  • 23 Aug 2017 Preclinical trials in Asthma in New Zealand (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top